Richard Francis reports TEVA share sales

Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.

The filing also shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026 reported as compensation.

Insights

Insider Transactions Analyst

Large open-market sales by an individual insider across February–March 2026.

Richard Francis reported three sales totaling 913, ,?006 shares across 02/17/2026, 03/03/2026, and 03/04/2026, with aggregate proceeds shown across each transaction. The filing also discloses a 42,452 RSU vesting on 03/05/2026 as compensation.

These items are routine disclosures of insider liquidity and compensation; cash‑flow treatment and any trading plan references are not provided in the excerpt. Subsequent filings may provide plan details or trading‑plan status.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sales did Richard Francis report in the TEVA Form 144?

Richard Francis reported sales of 447,678, 442,935, and 23,393 ordinary shares on 02/17/2026, 03/03/2026, and 03/04/2026, respectively, with proceeds listed for each transaction.

How much proceeds were reported for the TEVA insider sales?

The filing lists proceeds of $15,324,799.05, $14,333,332.31, and $759,442.05 for the three sales on 02/17/2026, 03/03/2026, and 03/04/2026.

Did the TEVA filing show any equity vesting for the insider?

Yes. The filing shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026, categorized as compensation in the excerpt.

Does the Form 144 excerpt state whether proceeds went to the company or selling holder?

The excerpt lists the selling transactions and proceeds per sale attributed to Richard Francis; it does not state that proceeds were received by the issuer or provide any use‑of‑proceeds detail.

Is there evidence of a trading plan or restriction in the TEVA excerpt?

The provided excerpt does not include language about a trading plan, Rule 10b5‑1 plan, or trading restrictions; no such plan details are disclosed in the text shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:26 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001673277
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Francis Richard D
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	PRESIDENT AND CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	20025	634159.70	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			42452	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	02/17/2026	447678	15324799.05
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	442935	14333332.31
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/04/2026	23393	759442.05

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. SHARES WERE SOLD PURSUANT TO A 10B51 PLAN ESTABLISHED IN NOV 2025.
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)